Medication Adjustments for Uncontrolled Diabetes with Impaired Renal Function

Introduction to Medication Adjustments

The American Diabetes Association and the National Kidney Foundation recommend determining the patient's exact eGFR to guide metformin dosing and then add an SGLT2 inhibitor (if eGFR ≥30 ml/min/1.73m²) while reducing or discontinuing gliclazide to minimize hypoglycemia risk 1

For patients with eGFR ≥60 ml/min/1.73m², the Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends continuing metformin 1000mg BID (current dose is appropriate) 2, 1
For patients with eGFR 45-59 ml/min/1.73m², the American College of Physicians recommends continuing metformin 1000mg BID without mandatory dose reduction, but considering reducing dose if patient has advanced age or concomitant liver disease 2, 3, 1
For patients with eGFR 30-44 ml/min/1.73m², the National Institute for Health and Care Excellence (NICE) recommends reducing metformin to half the maximum dose (500mg daily or 500mg BID maximum) 2, 1, 4

The American Heart Association recommends adding an SGLT2 inhibitor immediately if eGFR ≥30 ml/min/1.73m², as this is a Grade 1A recommendation that takes priority over other glucose-lowering agents for patients with diabetes and CKD 2, 1
The European Association for the Study of Diabetes recommends choosing SGLT2 inhibitor agents with documented kidney/cardiovascular benefits (empagliflozin, dapagliflozin, or canagliflozin) 2, 1

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends reducing or discontinuing gliclazide when adding SGLT2 inhibitor to prevent hypoglycemia, as sulfonylureas combined with SGLT2 inhibitors significantly increase hypoglycemia risk 2, 5, 1

The American Diabetes Association recommends adding a long-acting GLP-1 receptor agonist as third-line therapy if diabetes remains uncontrolled despite metformin and SGLT2 inhibitor 1

The National Kidney Foundation recommends monitoring renal function every 3-6 months if eGFR <60 ml/min/1.73m², and at least annually if eGFR ≥60 ml/min/1.73m² 2, 1, 3
The American College of Physicians recommends checking vitamin B12 levels if patient has been on metformin >4 years 1, 3

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends temporarily withholding SGLT2 inhibitor during prolonged fasting, surgery, or critical medical illness (increased ketosis risk) 2

The European Association for the Study of Diabetes recommends not continuing metformin at full dose if eGFR 30-44 ml/min/1.73m², as this significantly increases lactic acidosis risk 2
The American Heart Association recommends not adding insulin or additional sulfonylureas before trying SGLT2 inhibitor and GLP-1 RA, as these have superior cardiorenal outcomes 1